Annual General Meeting in ALK on 23 March 2023
ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 23 March 2023 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Aduro Clean Technologies Increases Size of Private Placement to $4 Million29.3.2023 02:12:40 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SARNIA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into feedstocks and higher-value fuels, is pleased to announce that, further to its news release dated March 8, 2023, it has increased the size of its non-brokered private placement of units (the “Units”) at $0.93 per Unit for gross proceeds of a minimum of $1,999,965 and up to a maximum of $4,000,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”) at a price o
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform28.3.2023 22:05:00 CEST | Press release
SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. “This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disor
Development of the Annual General Meeting of the BANK of Greenland28.3.2023 22:03:19 CEST | Press release
Minutes of General Meeting To Nasdaq OMX Copenhagen 28 March 2022 Company announcement no. 05/2023 Development of the Annual General Meeting of the BANK of Greenland Today, the BANK of Greenland held its Annual General Meeting in accordance with the Articles of Association and the previously published notice convening the meeting. The Annual General Meeting was attended by shareholders representing 1,049,468 votes, of which 612,498 votes were given by proxy to the Board of Directors, 62,821 votes were covered by instructions to holders of power of attorney and 115,455 votes of correspondance. The Board of Directors' Report on the Bank's activities during the past year The Chairman of the Board of Directors Gunnar í Liða presented the Board of Directors' report on the Bank's activities during the past year. The report of the Board of Directors was noted. The Chairman's report can be viewed on the Bank's website at www.banken.gl. The minutes of the Annual General Meeting will also be pub
Forløb af ordinær generalforsamling i GrønlandsBANKEN28.3.2023 22:03:19 CEST | pressemeddelelse
Referat af Generalforsamling Til Nasdaq OMX Copenhagen 28. marts 2023 Selskabsmeddelelse nr. 05/2023 Forløb af ordinær generalforsamling i GrønlandsBANKEN GrønlandsBANKEN har i dag afholdt ordinær generalforsamling i henhold til vedtægterne og tidligere offentliggjort indkaldelse. Generalforsamlingen var repræsenteret med 1.049.468 stemmer, heraf var 612.498 stemmer givet som fuldmagt til bestyrelsen, 62.821 stemmer var givet som instruktionsfuldmagt, mens 115.455 var afgivet som brevstemme. Bestyrelsens beretning om bankens virksomhed i det forløbne år Bestyrelsesformand Gunnar í Liða aflagde bestyrelsens beretning om bankens virksomhed i det forløbne år. Bestyrelsens beretning blev taget til efterretning. Formandens beretning kan ses på bankens hjemmeside www.banken.gl Generalforsamlingens protokollat vil senest 14 dage efter generalforsamlingens afholdelse ligeledes blive lagt på bankens hjemmeside. Godkendelse af årsrapporten for 2022, meddelelse om decharge for bestyrelse og direk
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants28.3.2023 22:00:00 CEST | Press release
Company announcement – No. 8 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 34,594 divided into 34,594 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which ar